Navigation Links
CyberKnife to be Focus of Numerous Presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting

SUNNYVALE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

The accepted abstracts, which will be presented as posters or oral presentations, focus on the use of the CyberKnife® Robotic Radiosurgery System to treat tumors located throughout the body including the prostate, lung, brain, spine, liver, pancreas, head and neck.

"The depth and breadth of research presented at this year's ASTRO meeting is a testament to the growing clinical acceptance of the CyberKnife System and the important role it is playing in the treatment of cancer," said Euan Thomson, Ph.D., president and CEO of Accuray.

Highlights of the research that will be showcased include seven presentations focusing on the use of CyberKnife radiosurgery to treat prostate cancer. CyberKnife prostate procedures from July-September 2009 increased 21 percent over the same period the previous year, confirming the increasing demand for this treatment option. To date, CyberKnife radiosurgery has been used to treat more than 4,000 men with prostate cancer.

Additionally, Accuray will host a number of presentations in the company's booth (#1526) reporting on experience with CyberKnife radiosurgery. Presenters include Eric Lartigau, M.D., Ph.D., from Centre Oscar Lambret; Xiaodong Wu, Ph.D., from University of Miami; Donald B. Fuller, M.D., from CyberKnife Centers of San Diego; Brian T. Collins, M.D., from Georgetown University Hospital; Joe Y. Chang, M.D., Ph.D., from M. D. Anderson Cancer Center; Debra Freeman, M.D., from Naples Radiation Oncology; Sonja Dieterich, Ph.D., and Iris Gibbs, M.D., from Stanford University Hospital; Kim Huang, M.D., from University of California San Francisco; and Greg Spurlock from US Radiosurgery.

Accuray will be exhibiting at booth #1526. For more information on the accepted abstracts, posters and in-booth presentations related to the CyberKnife System please visit

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to publication of clinical results, clinical acceptance of products, and growing demand for treatments are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2009 fiscal year and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

Omar Dawood, M.D., MPH

SOURCE Accuray Incorporated

SOURCE Accuray Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
2. Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
3. CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth
4. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
5. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
6. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
7. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
8. FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics Focus Diagnostics
9. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
10. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
11. Health Reform Bills Still Lack Strategic Focus on Health Workforce
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... LONDON , November 25, 2015 Developmental, ... key role in boosting the profitability of pharmaceutical products, ... Developmental, commercial, and regulatory/legal strategies all play ... says GBI Research . --> ... all play a key role in boosting the profitability of pharmaceutical ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
Breaking Medicine News(10 mins):